Comparison of the performance of implantable cardioverter-defibrillator leads among manufacturers.

Durata Implantable cardioverter-defibrillator Lead Linox Quattro

Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 06 08 2019
accepted: 30 09 2019
pubmed: 7 11 2019
medline: 19 8 2021
entrez: 7 11 2019
Statut: ppublish

Résumé

Leads are often considered the weakest link in implantable cardioverter-defibrillator (ICD) systems, and lead dysfunction is a major concern for ICD recipients. The aim of this study was to compare the lead performance from three different manufacturers. We retrospectively reviewed consecutive patients who underwent ICD system implantation at Chiba University Hospital, Japan, between March 2008 and September 2017. The following leads were implanted in our center: Durata (St. Jude Medical, St. Paul, MN, USA, now Abbott) (n = 105), Linox and Linox A total of 297 ICD leads were analyzed. Failure rates for Durata, Linox/Linox In this single-center retrospective study, the performance of Sprint Quattro was lower than the performance of Linox/Linox

Sections du résumé

BACKGROUND BACKGROUND
Leads are often considered the weakest link in implantable cardioverter-defibrillator (ICD) systems, and lead dysfunction is a major concern for ICD recipients. The aim of this study was to compare the lead performance from three different manufacturers.
METHODS METHODS
We retrospectively reviewed consecutive patients who underwent ICD system implantation at Chiba University Hospital, Japan, between March 2008 and September 2017. The following leads were implanted in our center: Durata (St. Jude Medical, St. Paul, MN, USA, now Abbott) (n = 105), Linox and Linox
RESULTS RESULTS
A total of 297 ICD leads were analyzed. Failure rates for Durata, Linox/Linox
CONCLUSIONS CONCLUSIONS
In this single-center retrospective study, the performance of Sprint Quattro was lower than the performance of Linox/Linox

Identifiants

pubmed: 31691064
doi: 10.1007/s10840-019-00640-w
pii: 10.1007/s10840-019-00640-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

133-139

Auteurs

Yusuke Kondo (Y)

Department of Advanced Cardiorhythm Therapeutics, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. yuusukondou-circ@umin.ac.jp.

Masahiro Nakano (M)

Department of Advanced Cardiorhythm Therapeutics, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

Takatsugu Kajiyama (T)

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Miyo Nakano (M)

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Tomohiko Hayashi (T)

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Ryo Ito (R)

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Haruhiro Takahira (H)

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Yoshio Kobayashi (Y)

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH